{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:14:05Z","timestamp":1783955645091,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T00:00:00Z","timestamp":1504137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/bjc.2017.288","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T22:47:37Z","timestamp":1504219657000},"page":"1258-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies"],"prefix":"10.1038","volume":"117","author":[{"given":"Monica M","family":"Mita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain C","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kirschmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Statkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamelesh K","family":"Sankhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian R","family":"Chirieac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J","family":"Rodig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Bannerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"BFbjc2017288_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4161\/cbt.214","volume":"2","author":"M Alonso","year":"2003","unstructured":"Alonso M, Tamasdan C, Miller DC, Newcomb EW (2003) Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2: 139\u2013150.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2017288_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14: 130\u2013146.","journal-title":"Nat Rev Drug Discov"},{"key":"BFbjc2017288_CR3","doi-asserted-by":"publisher","first-page":"10120","DOI":"10.1038\/srep10120","volume":"5","author":"EK Baker","year":"2015","unstructured":"Baker EK, Taylor S, Gupte A, Sharp PP, Walia M, Walsh NC, Zannettino AC, Chalk AM, Burns CJ, Walkley CR (2015) BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Sci Rep 5: 10120.","journal-title":"Sci Rep"},{"key":"BFbjc2017288_CR4","doi-asserted-by":"publisher","first-page":"18863","DOI":"10.18632\/oncotarget.4321","volume":"6","author":"TN Beck","year":"2015","unstructured":"Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R (2015) Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget 6: 18863\u201318874.","journal-title":"Oncotarget"},{"key":"BFbjc2017288_CR5","doi-asserted-by":"publisher","first-page":"e108371","DOI":"10.1371\/journal.pone.0108371","volume":"9","author":"RN Booher","year":"2014","unstructured":"Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P (2014) MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS One 9: e108371.","journal-title":"PLoS One"},{"key":"BFbjc2017288_CR6","first-page":"4320","volume":"60","author":"MA Brantley","year":"2000","unstructured":"Brantley MA, Harbour JW (2000) Inactivation of retinolbastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 60: 4320\u20134323.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR7","doi-asserted-by":"publisher","first-page":"16286","DOI":"10.1074\/jbc.M110.108167","volume":"285","author":"JR Burke","year":"2010","unstructured":"Burke JR, Deshong AJ, Pelton JG, Rubin SM (2010) Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem 285: 16286\u201316293.","journal-title":"J Biol Chem"},{"key":"BFbjc2017288_CR8","doi-asserted-by":"publisher","first-page":"9270","DOI":"10.1158\/0008-5472.CAN-06-1758","volume":"66","author":"D Cai","year":"2006","unstructured":"Cai D, Latham VM Jr, Zhang X, Shapiro GI (2006) Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66: 9270\u20139280.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR9","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1158\/0008-5472.CAN-09-3578","volume":"70","author":"R Chen","year":"2010","unstructured":"Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W (2010) Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 70: 6587\u20136597.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR10","doi-asserted-by":"publisher","first-page":"16912","DOI":"10.18632\/oncotarget.4857","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Tat TT, Misra S, Hill BT, Smith MR, Almasan A, Mazumder S (2015) Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. Oncotarget 6: 16912\u201316925.","journal-title":"Oncotarget"},{"key":"BFbjc2017288_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.molonc.2014.07.025","volume":"9","author":"N Cook","year":"2015","unstructured":"Cook N, Hansen AR, Siu LL, Abdul Razak AR (2015) Early phase clinical trials to identify optimal dosing and safety. Mol Oncol 9: 997\u20131007.","journal-title":"Mol Oncol"},{"key":"BFbjc2017288_CR12","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1158\/0008-5472.CAN-04-0204","volume":"64","author":"ZN Demidenko","year":"2004","unstructured":"Demidenko ZN, Blagosklonny MV (2004) Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 64: 3653\u20133660.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR13","doi-asserted-by":"publisher","first-page":"e59588","DOI":"10.1371\/journal.pone.0059588","volume":"8","author":"BM Desai","year":"2013","unstructured":"Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M (2013) The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One 8: e59588.","journal-title":"PLoS One"},{"key":"BFbjc2017288_CR14","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2006-03-013771","volume":"109","author":"I Dzhagalov St","year":"2007","unstructured":"Dzhagalov I St, John A, He YW (2007) The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 109: 1620\u20131626.","journal-title":"Blood"},{"key":"BFbjc2017288_CR15","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1021\/cr400071f","volume":"113","author":"D Eick","year":"2013","unstructured":"Eick D, Geyer M (2013) The RNA polymerase II carboxy-terminal domain (CTD) code. Chem Rev 113: 8456\u20138490.","journal-title":"Chem Rev"},{"key":"BFbjc2017288_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4161\/cbt.12.7.16475","volume":"12","author":"G Feldmann","year":"2011","unstructured":"Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD (2011) Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 12: 598\u2013609.","journal-title":"Cancer Biol Ther"},{"key":"BFbjc2017288_CR17","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-09-1107","volume":"70","author":"G Feldmann","year":"2010","unstructured":"Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A, Nelkin BD (2010) Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 70: 4460\u20134469.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR18","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/leu.2015.31","volume":"29","author":"J Flynn","year":"2015","unstructured":"Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC (2015) Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 29: 1524\u20131529.","journal-title":"Leukemia"},{"key":"BFbjc2017288_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/1535-7163.MCT-11-0167","volume":"10","author":"W Fu","year":"2011","unstructured":"Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, Altiok S, Pledger WJ (2011) The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 10: 1018\u20131027.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2017288_CR20","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","volume":"133","author":"J Gerdes","year":"1984","unstructured":"Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell prolfieration-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710\u20131715.","journal-title":"J Immunol"},{"key":"BFbjc2017288_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2015.10","volume":"29","author":"GP Gregory","year":"2015","unstructured":"Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, Lefebure M, Martin BP, Dawson MA, Johnstone RW, Shortt J (2015) CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B- cell lymphoma in vivo. Leukemia 29: 1437\u20131441.","journal-title":"Leukemia"},{"key":"BFbjc2017288_CR22","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-04-0229","volume":"10","author":"RI Haddad","year":"2004","unstructured":"Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM Jr, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI (2004) A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 10: 4680\u20134687.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017288_CR23","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cort\u00e9s J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V (2016) Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76: 2301\u20132313.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","volume":"19","author":"MK Jang","year":"2005","unstructured":"Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 19: 523\u2013534.","journal-title":"Mol Cell"},{"key":"BFbjc2017288_CR25","first-page":"7410","volume":"63","author":"J Jiang","year":"2003","unstructured":"Jiang J, Matranga CB, Cai D, Latham VM, Zhang X, Lowell AM, Martelli F, Shapiro GI (2003) Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 63: 7410\u20137422.","journal-title":"Cancer Res"},{"key":"BFbjc2017288_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1517\/14728222.2010.525221","volume":"14","author":"N Johnson","year":"2011","unstructured":"Johnson N, Shapiro GI (2011) Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 14: 1199\u20131212.","journal-title":"Expert Opin Ther Targets"},{"key":"BFbjc2017288_CR27","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D\u2019Andrea AD, Balma\u00f1a J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI (2016) CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep 17: 2367\u20132381.","journal-title":"Cell Rep"},{"key":"BFbjc2017288_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dgd.12138","volume":"56","author":"T Kawauchi","year":"2014","unstructured":"Kawauchi T (2014) Cdk5 regulates multiple cellular events in neural development, function and disease. Dev Growth Differ 56: 335\u2013348.","journal-title":"Dev Growth Differ"},{"key":"BFbjc2017288_CR29","doi-asserted-by":"publisher","first-page":"7060","DOI":"10.1002\/j.1460-2075.1996.tb01097.x","volume":"15","author":"M Kitagawa","year":"1996","unstructured":"Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K, Kato JY, Segawa K, Yoshida E, Nishimura S, Taya Y (1996) The consensus motif for phosphorylation by cyclin D1-cdk4 is different from that for phosphorylation by cyclin A\/E-cdk2. EMBO J 15: 7060\u20137069.","journal-title":"EMBO J"},{"key":"BFbjc2017288_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","volume":"125","author":"SK Kumar","year":"2015","unstructured":"Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK Mayo Phase 2 Consortium (2015) Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 125: 443\u2013448.","journal-title":"Blood"},{"key":"BFbjc2017288_CR31","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI (2012) Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119: 4597\u20134607.","journal-title":"Blood"},{"key":"BFbjc2017288_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/1947601912473305","volume":"3","author":"JI Macdonald","year":"2012","unstructured":"Macdonald JI, Dick FA (2012) Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function. Genes Cancer 3: 619\u2013633.","journal-title":"Genes Cancer"},{"key":"BFbjc2017288_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15: 122.","journal-title":"Genome Biol"},{"key":"BFbjc2017288_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153\u2013166.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017288_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.clbc.2013.10.016","volume":"14","author":"MM Mita","year":"2014","unstructured":"Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, Bannerji R, Shapiro CL (2014) Randomized phase II trial of the cyclin- dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 14: 169\u2013176.","journal-title":"Clin Breast Cancer"},{"key":"BFbjc2017288_CR36","doi-asserted-by":"publisher","first-page":"e02872","DOI":"10.7554\/eLife.02872","volume":"3","author":"AM Narasimha","year":"2014","unstructured":"Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF (2014) Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. Elife 3: e02872.","journal-title":"Elife"},{"key":"BFbjc2017288_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1479-5876-11-259","volume":"11","author":"JJ Nemunaitis","year":"2013","unstructured":"Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou YM, Statkevich P, Yao SL, Bannerji R (2013) A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 11: 259.","journal-title":"J Transl Med"},{"key":"BFbjc2017288_CR38","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM (2010) Dinaciclib (SCH 727965), a novel and potent cyclin- dependent kinase inhibitor. Mol Cancer Ther 9: 2344\u20132353.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2017288_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/ml100051d","volume":"1","author":"K Paruch","year":"2010","unstructured":"Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, Keertikart K, Knutson C, McKittrick B, Rivera J, Rossman R, Tucker G, Fischmann T, Hruza A, Madison V, Nomeir AA, Wang Y, Kirschmeier P, Lees E, Parry D, Sgambellone N, Seghezzi W, Schultz L, Shanahan F, Wiswell D, Xu X, Zhou Q, James RA, Paradkar VM, Park H, Rokosz LR, Stauffer TM, Guzi TJ (2010) Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 1: 204\u2013208.","journal-title":"ACS Med Chem Lett"},{"key":"BFbjc2017288_CR40","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","volume":"113","author":"MA Phelps","year":"2009","unstructured":"Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT (2009) Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 113: 2637\u20132645.","journal-title":"Blood"},{"key":"BFbjc2017288_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10637-010-9563-7","volume":"30","author":"B Ramaswamy","year":"2012","unstructured":"Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH (2012) A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs 30: 629\u2013638.","journal-title":"Invest New Drugs"},{"key":"BFbjc2017288_CR42","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","volume":"24","author":"GI Shapiro","year":"2006","unstructured":"Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24: 1770\u20131783.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017288_CR43","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1101\/gad.11.11.1464","volume":"11","author":"RJ Sheaff","year":"1997","unstructured":"Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE (1997) Cyclin E-cdk2 is a regulator of p27Kip1. Genes Dev 11: 1464\u20131478.","journal-title":"Genes Dev"},{"key":"BFbjc2017288_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr CJ, Beach D, Shapiro GI (2016) Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 6: 353\u2013367.","journal-title":"Cancer Discov"},{"key":"BFbjc2017288_CR45","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138\u20131147.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2017288_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2013.11.020","volume":"83","author":"JJ Stephenson","year":"2014","unstructured":"Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, Statkevich P, Yao SL, Zhu Y, Zhou H, Small K, Bannerji R, Edelman MJ (2014) Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer 83: 219\u2013223.","journal-title":"Lung Cancer"},{"key":"BFbjc2017288_CR47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.18632\/oncotarget.2673","volume":"6","author":"B Taylor-Harding","year":"2015","unstructured":"Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR (2015) Cyclin E1 and RTK\/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget 6: 696\u2013714.","journal-title":"Oncotarget"},{"key":"BFbjc2017288_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205\u2013216.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc2017288_CR49","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1093\/emboj\/16.17.5334","volume":"16","author":"J Vlach","year":"1997","unstructured":"Vlach J, Hennecke S, Amati B (1997) Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16: 5334\u20135344.","journal-title":"EMBO J"},{"key":"BFbjc2017288_CR50","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]- fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773\u20131782.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017288_CR51","doi-asserted-by":"publisher","first-page":"12738","DOI":"10.1074\/jbc.272.19.12738","volume":"272","author":"T Zarkowska","year":"1997","unstructured":"Zarkowska T, Mittnacht S (1997) Differential phosphorylation of the retinoblastoma protein by G1\/S cyclin-dependent kinases. J Biol Chem 272: 12738\u201312746.","journal-title":"J Biol Chem"},{"key":"BFbjc2017288_CR52","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00280-012-1967-y","volume":"70","author":"D Zhang","year":"2012","unstructured":"Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P (2012) Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemother Pharmacol 70: 891\u2013898.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017288","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:37:50Z","timestamp":1692959870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFbjc2017288"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.288","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,31]]},"assertion":[{"value":"3 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JP, KAS, Y-MJ, PK, DZ, YZ, PS, and RB are present or former employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. JMC has served as a consultant for Agios, received grants from Merck & Co., Inc., and received travel\/ accommodations from Roche and Bristol Myers Squibb (BMS). LRC has served as a consultant for Wilcox & Savage, Medical Science Affiliates, and Shook, Hardy & Bacon, and has given expert testimony for Shook, Hardy & Bacon, and has received royalties from Springer. SR has served as a member of the board for Perkin Elmer Inc., has received grants from BMS, and has received payment for lectures from BMS. GIS has received consultant fees from Lilly, Pfizer, G1 Therapuetics, Vertex, and EMD Serono. His institution has received grants from Lilly and Pfizer. An SRA related to immunohistochemical staining of skin and tumour biopsies, under which there will be payment from Merck to the Brigham and Women\u2019s Hospital for work completed, will be executed in relation to this work. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}